• An international R&D and manufacturing enterprise powered by biotechnology at its core and an AI-driven global cross-border technology engine. The company is a US federally registered corporation invested in by Nexteye, a publicly listed Korean company.
• Dedicated to the independent R&D of cutting-edge biotechnology products and breakthrough innovation in highly active biological raw materials, it holds multiple core processes and patented formulas, building a full-chain technological barrier from raw material development to finished product output. The IEONA series life technology BIO product line has been successfully developed, featuring three core products: GeneAKG, Myo-Inositol, and 150-year-old Mountain Ginseng Cultured Root Cell Drinks – alongside the Pulsed Current GeneAKG Anti-Aging Skincare Series.
• The group boasts three laboratories operated under a US-South Korea scientist R&D alliance, along with its own GMP-compliant manufacturing facilities: a cosmetics factory, a South Korean nail product GMP factory, and a medical injection and hyaluronic acid GMP factory.
• The Group’s venture capital division covers semiconductor inspection, medical aesthetics, biotechnology, cosmeceuticals, and daily chemicals. With over USD 1 billion in managed funds and peak daily stock trading volume of USD 250 million, its financial position remains solid.
• The Group currently holds controlling stakes in 7 internationally listed companies and investments in 54 companies, with a service network covering 40,000 retail outlets worldwide. Its partners include Samsung, LG, SK, Hyundai, BYD, and other renowned enterprises, earning it a strong market reputation.

• The Group is at the industry’s advanced level in biomedical technology: it has obtained 141 technology patents and achieved multiple significant milestones, including the industry-leading Phase III clinical approval for human medical injectable hyaluronic acid granted by the Korean government, the 2022 launch of the genetic ingredient Gene-AKG, the 2024 release of skincare products featuring microcurrent pulse patent technology, and an ongoing liver cancer targeted regulation program.
• Committed to providing global consumers and partners with scientifically grounded, quality-controlled health products as well as efficient, cost-effective AI cross-border technical services.
• In global markets, the company strictly complies with relevant regulations, focusing on the import and sales of cross-border goods (manufactured in South Korea and the US, dispatched from bonded warehouses). Adopting the standard cross-border personal-use model, products are shipped globally from South Korea via fully compliant bonded warehouses, backed by a hassle-free 7-day return policy to effectively safeguard consumer rights.

Important Notice: In the Chinese market, if you encounter unverified rumors concerning the company involving multi-level team compensation or bonus distribution, please do not believe them, to avoid damage to your personal rights and interests.